Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries

Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK). An obser...

Descripción completa

Detalles Bibliográficos
Autores: Tack, Jan|||0000-0002-3206-6704, Stanghellini, Vincenzo|||0000-0003-0559-4875, Mearin, Fermín, Yiannakou, Yan, Layer, Peter, Coffin, Benoit|||0000-0002-0606-4158, Simren, Magnus, Mackinnon, Jonathan, Wiseman, Gwen, Marciniak, Anne, Brotons, Carlos|||0000-0001-9388-6581
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:286565
Acceso en línea:https://ddd.uab.cat/record/286565
https://dx.doi.org/urn:doi:10.1186/s12876-019-0985-1
Access Level:acceso abierto
Palabra clave:Economic Analysis
Europe
Healthcare resource utilisation
IBS
IBS-C
Descripción
Sumario:Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK). An observational, one year retrospective-prospective (6 months each) study of patients diagnosed in the last five years with IBS-C (Rome III criteria) and moderate to severe disease at inclusion (IBS Symptom Severity Scale score ≥ 175). The primary objective was to assess the direct cost to European healthcare systems. Five hundred twenty-five patients were included, 60% (range: 43.1-78.8%) suffered from severe IBS-C. During follow-up 11.1-24.0% of patients had a hospitalisation/emergency room (ER) visit, median stay range: 1.5-12.0 days and 41.1-90.4% took prescription drugs for IBS-C. 21.4-50.8% of employed patients took sick leave (mean: 11.6-64.1 days). The mean annual direct cost to the healthcare systems was €937.1- €2108.0. The total direct cost (combined costs to healthcare systems and patient) for IBS-C was €1421.7-€2487.1. IBS-C is not a life-threatening condition; however, it has large impact on healthcare systems and society. Direct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver being hospitalisations/ER visits.

Similares en LA Referencia